Grant: CIHR Clinician Scientist - Phase 1
University of Toronto
$172,500.00
Control of cardiac metabolism and growth by DJ-1
FY 2011-12
Summary
Heart failure is the leading cause of morbidity and mortality in Canada and has been identified as the second leading cause of extended hospital stays. In the adult, the heart is incapalbe of regenerating itself. This renders the heart particularly vulnerable to injury. Our existing medical therapy can only slow the progression of the disease. Alternatives to medical therapy are limited to transplantation or mechanical devices. The quality of life and the prognosis for this group of patients remains poor. In addition, more than $1 billion of Canada's annual health budget is being spent for the care of patients with HF, rendering this disease an ever increasing socioeconomic burden. Therefore, it is exceedingly important to consider alternative and/or complementary approaches that allow discovery of alternate treatment strategies that will effectively restrict cardiomyocyte loss and hypertrophy (see below). Providing a new and effective therapy for HF will not only improve the quality of life for patients but also reduce the costs associated with patient care. DJ-1, a protein implicated in early-onset familial forms of Parkinson's disease, is highly expressed in the heart. Its biological function in these cells, however, remains elusive. We have data to support a protective role for DJ-1 in preventing the development of heart failure. Another important finding is that DJ-1 is involved in maintaining a balance of metabolism within heart muscle cells. This proposal describes detailed studies that would be instrumental in helping us defining the role of DJ-1 in the heart. As such, DJ-1 may represent an unique target for the development of novel therapies for the treatment of heart failure.
Department
Program
CIHR Clinician Scientist - Phase 1
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
244295
Name
Billia Filio
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Clinician Scientist
Projecttitle
Control of cardiac metabolism and growth by DJ-1
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$172,500
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 1
Keyworddelim
Heart Failure; Knockout Animals; Metabolic Transformation
Abstract
Heart failure is the leading cause of morbidity and mortality in Canada and has been identified as the second leading cause of extended hospital stays. In the adult, the heart is incapalbe of regenerating itself. This renders the heart particularly vulnerable to injury. Our existing medical therapy can only slow the progression of the disease. Alternatives to medical therapy are limited to transplantation or mechanical devices. The quality of life and the prognosis for this group of patients remains poor. In addition, more than $1 billion of Canada's annual health budget is being spent for the care of patients with HF, rendering this disease an ever increasing socioeconomic burden. Therefore, it is exceedingly important to consider alternative and/or complementary approaches that allow discovery of alternate treatment strategies that will effectively restrict cardiomyocyte loss and hypertrophy (see below). Providing a new and effective therapy for HF will not only improve the quality of life for patients but also reduce the costs associated with patient care. DJ-1, a protein implicated in early-onset familial forms of Parkinson's disease, is highly expressed in the heart. Its biological function in these cells, however, remains elusive. We have data to support a protective role for DJ-1 in preventing the development of heart failure. Another important finding is that DJ-1 is involved in maintaining a balance of metabolism within heart muscle cells. This proposal describes detailed studies that would be instrumental in helping us defining the role of DJ-1 in the heart. As such, DJ-1 may represent an unique target for the development of novel therapies for the treatment of heart failure.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Billia, Filio
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $172,500~ $0~